Four Critical Factors for Clinical Trial Budget Success

Published on:
May 1, 2020
Written by:
Christopher Rao

Planning a relevant and accurate budget, regardless of the trial phase or indication, can be one of the most challenging aspects of the clinical trial process.

Though it is one of the most integral and essential components of the program, clinical trial budgets are often overly bulky, missing fine details or just plain inaccurate. This results in the need to re-forecast and re-plan, delay or even close a trial due to insufficient or improperly allocated funds.

How can you ensure your clinical trial budget is airtight? By taking a realistic approach to clinical trial budget planning and execution. Consider these four factors when developing your budget:

Chris Rao
  • Be realistic: Unrealistic timelines and cost ceilings are frequently pushed down from the top. Understand where you can shave time (and costs) off your trial plan and where it is simply not possible. A realistic view of costs, though sometimes painful, will help you plan for the necessities of the trial and will avoid “wishful thinking”. Examples of timelines which can only be minimally shifted are institutional startup timelines (such as IRB review) and regulatory timelines set by FDA or other agencies.
  • Understand your indication: Each indication is unique as it relates to subject accrual, institutional reimbursement and standard of care vs. protocol-required procedures. By having a firm grasp on the nuances of your patient population, you will be better equipped to estimate subject costs, institutional fees and enrollment rates at the site level, all of which have a direct budgetary impact.
  • Look for hidden costs: Sponsor companies are often plagued by “hidden” costs, such as clinical equipment rentals and unanticipated invoiceable study procedures at the site level, as well as study delays and other timeline changes which increase costs. Plan for the unexpected by building a cushion into your trial budget. Some sponsor companies will increase study-wide costs by a 5-10% margin, ensuring that an unanticipated delay or increased cost is not a budget-breaker.
  • Compare Service Providers: Not all service providers are created equally. When budgeting for items such as data management, clinical site monitoring and pharmacovigilance, your chosen service provider should be able to provide you with a clear, concise and understandable explanation of projected charges. While change orders are sometimes a necessary evil, a good service provider should ensure that these are the exception, rather than the norm.

Taking a practical and measured approach to clinical trial budgeting will help you build an initial trial budget that is as accurate as possible and provide some cushion to help weather unexpected storms that may pop up during your trial. With these factors in mind, you’ll be well on your way to success, without breaking the bank (or your budget).

Chris Rao is the Vice President, Clinical Development. Chris has over 15 years of experience in clinical research, with a focus on trial design and management.


Related news

Events October 22, 2021
Event: OCT Nordics 2021
Meet us at OCT Nordics October 26- 27, 2021.
Events October 22, 2021
Event: OCT New England
Meet us at Outsourcing in Clinical Trials New England.
Publications October 7, 2021
Tips for Successful Sponsor and CRO Collaboration
The relationship between Sponsor and CRO is a critical aspect of an effective and timely clinical trial; when the relationship is transparent and smooth, the benefit is seen by all parties.
News June 8, 2021
Alira Health Expands Its Global Clinical and Data Capabilities Through the Acquisition of CROS NT
We have acquired CROS NT, a data-driven Contract Research Organization (CRO) headquartered in Italy with offices across Europe and the United States. CROS NT provides high quality,(...)
Multimedia June 4, 2021
Managing Relationships Between CROs and Clinical Trial Sites
Join us in this special episode of Alira Health’s Transformation Talks with a full cast of Alira Health experts.
Publications April 6, 2021
Unlocking the Database Lock Process
In our latest whitepaper, in collaboration with CROS NT, Alira Health’s Vice President Clinical Development, Christopher Rao and Amanda Cross, US Country Manager Executive Director,(...)
Clinical Regulatory
News January 7, 2021
Alira Health Adds CMC Services through Acquisition of Chamow & Associates
We have acquired Chamow & Associates (, a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.